LBLTF: AI 评分 51/100 — AI 分析 (4月 2026)

Lattice Biologics Ltd. develops, manufactures, and markets biologic products for bone regeneration in dental, spine, and orthopedic applications. The company offers amniotic fluid-based products and traditional allografts, targeting a range of surgical procedures.

Key Facts: AI Score: 51/100 Sector: Healthcare

公司概况

概要：

Lattice Biologics Ltd. is a biotech company specializing in the development and marketing of biologic products for bone regeneration, including amniotic fluid-based products and allografts, primarily serving the dental, spine, and orthopedic markets globally, with a focus on enhancing surgical outcomes.

LBLTF是做什么的？

Lattice Biologics Ltd., headquartered in Belgrade, Montana, is a biotech company focused on developing, manufacturing, and marketing biologic solutions for bone regeneration. The company's products are utilized in a variety of surgical applications across dental, spine, and general orthopedic fields. Lattice Biologics develops novel amniotic fluid-based products, including AmnioBoost and AmnioBlast, alongside a comprehensive portfolio of traditional allografts. These allografts encompass spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix options. The company's products are designed to enhance fusion in spine surgery, aid in breast reconstruction post-mastectomy, promote bone regeneration in foot and ankle procedures, and facilitate skull healing after neurosurgery. They also support wound repair in burn victims, hernia repair, and subchondral bone defect repair in knee and other joint surgeries, as well as address sports medicine indications, such as anterior and posterior cruciate ligament repair. Lattice Biologics aims to provide innovative and effective solutions for bone regeneration, addressing unmet needs in the surgical landscape.

LBLTF的投资论点是什么？

Lattice Biologics Ltd. presents a focused investment opportunity within the bone regeneration market. The company's amniotic fluid-based products, such as AmnioBoost and AmnioBlast, offer potential for growth in the regenerative medicine sector. With a gross margin of 41.4%, the company demonstrates an ability to generate revenue from its products. Key value drivers include the expansion of its product portfolio and penetration into new geographic markets. Upcoming catalysts include potential regulatory approvals for its amniotic fluid-based products and strategic partnerships to expand distribution channels. Potential risks include the company's negative profit margin of -60.2% and reliance on the OTC market for trading, which may impact liquidity and valuation.

LBLTF在哪个行业运营？

Lattice Biologics operates within the medical devices industry, specifically focusing on bone regeneration. The industry is characterized by increasing demand for minimally invasive surgical techniques and regenerative medicine solutions. The competitive landscape includes companies offering allografts and synthetic bone substitutes. Lattice Biologics differentiates itself through its amniotic fluid-based products. The global bone graft and substitutes market is projected to reach billions of dollars by 2026, driven by an aging population and increasing incidence of orthopedic disorders.

Medical - Devices

Healthcare

LBLTF有哪些增长机遇？

Expansion of Amniotic Fluid-Based Products: Lattice Biologics can capitalize on the growing demand for regenerative medicine by expanding the applications and market reach of its AmnioBoost and AmnioBlast products. The amniotic fluid market is projected to grow significantly, driven by its regenerative properties and potential in various therapeutic areas. Successful clinical trials and regulatory approvals could drive adoption by surgeons and healthcare providers, leading to increased revenue and market share. Timeline: Ongoing.
Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with established medical device companies or distributors can significantly expand Lattice Biologics' market access and sales reach. Leveraging existing distribution networks can accelerate product adoption and penetration into new geographic markets. These partnerships can also provide access to additional resources and expertise, enhancing the company's competitive position. Timeline: Ongoing.
Geographic Expansion: Expanding into new geographic markets, particularly in Europe and Asia-Pacific, represents a significant growth opportunity for Lattice Biologics. These regions have a growing demand for advanced bone regeneration products. Adapting products to meet local regulatory requirements and establishing distribution channels in these markets can drive revenue growth and diversification. Timeline: 2-3 years.
Product Portfolio Diversification: Diversifying the product portfolio beyond bone regeneration to include other regenerative medicine applications, such as wound healing and soft tissue repair, can expand Lattice Biologics' addressable market. Developing and launching new products in these areas can leverage the company's expertise in amniotic fluid-based technologies and address unmet clinical needs. Timeline: 3-5 years.
Clinical Trials and Research: Investing in clinical trials and research to demonstrate the efficacy and safety of its products can enhance Lattice Biologics' credibility and market acceptance. Positive clinical data can support regulatory approvals and drive adoption by surgeons and healthcare providers. Collaborating with leading research institutions and publishing scientific studies can further strengthen the company's reputation and competitive advantage. Timeline: Ongoing.

Gross Margin of 41.4% indicates the company's ability to generate revenue from its products.
Negative Profit Margin of -60.2% reflects ongoing challenges in achieving profitability.
Beta of 1.21 suggests the stock is more volatile than the overall market.
The company's focus on bone regeneration addresses a growing need in the dental, spine, and orthopedic markets.
Lattice Biologics' amniotic fluid-based products offer potential for growth in the regenerative medicine sector.

LBLTF提供哪些产品和服务？

Develops biologic products for bone regeneration.
Manufactures allografts for dental, spine, and orthopedic applications.
Markets products globally to healthcare providers and hospitals.
Offers amniotic fluid-based products like AmnioBoost and AmnioBlast.
Provides traditional allografts, including spinal, particulate, and soft tissue options.
Addresses a range of surgical applications, including spine fusion and bone regeneration.

LBLTF如何赚钱？

Develops and manufactures biologic products for bone regeneration.
Markets and sells these products to hospitals, surgeons, and other healthcare providers.
Generates revenue through direct sales and distribution agreements.

Hospitals and surgical centers
Orthopedic surgeons
Dental surgeons
Spine surgeons

Proprietary amniotic fluid-based product technology.
Established relationships with surgeons and hospitals.
Focus on bone regeneration in specific surgical applications.

什么因素可能推动LBLTF股价上涨？

Upcoming: Potential regulatory approvals for AmnioBoost and AmnioBlast products.
Ongoing: Expansion of distribution channels through strategic partnerships.
Ongoing: Clinical trials and research demonstrating product efficacy.
Ongoing: Geographic expansion into new markets.
Ongoing: Development of new products in related regenerative medicine areas.

LBLTF的主要风险是什么？

Ongoing: Negative profit margin and challenges in achieving profitability.
Potential: Competition from established medical device companies.
Potential: Regulatory hurdles and changes in healthcare policies.
Ongoing: Reliance on OTC market for trading, impacting liquidity and valuation.
Potential: Product liability claims.

LBLTF的核心优势是什么？

Proprietary amniotic fluid-based product technology.
Focus on bone regeneration in specific surgical applications.
Established relationships with surgeons and hospitals.
Comprehensive portfolio of allograft options.

LBLTF的劣势是什么？

Negative profit margin.
Reliance on OTC market for trading.
Limited market share compared to larger competitors.
Dependence on regulatory approvals for new products.

LBLTF有哪些机遇？

Expansion of amniotic fluid-based product applications.
Strategic partnerships and distribution agreements.
Geographic expansion into new markets.
Product portfolio diversification into related regenerative medicine areas.

LBLTF面临哪些威胁？

Competition from established medical device companies.
Regulatory hurdles and changes in healthcare policies.
Potential product liability claims.
Economic downturns affecting healthcare spending.

LBLTF的竞争对手是谁？

AlloSource — Focuses on allograft tissue for various surgical procedures. — (AGYTF)
Avenue Therapeutics Inc — Develops and commercializes therapies for unmet medical needs. — (AVNBF)
Biotech Resources — Offers regenerative medicine products and services. — (BJTRF)
Caladrius Biosciences Inc — Develops cell therapies for autoimmune and cardiovascular diseases. — (CALZF)
Clovis Oncology Inc — Focuses on developing targeted therapies for cancer treatment. — (CLVSF)

Key Metrics

MoonshotScore: 51/100

Company Profile

CEO: Donna Medina
Headquarters: Belgrade, US
Founded: 2010

AI Insight

AI analysis pending for LBLTF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Lattice Biologics Ltd. do?

Lattice Biologics Ltd. is a biotech company that develops, manufactures, and markets biologic products focused on bone regeneration. Their portfolio includes amniotic fluid-based products like AmnioBoost and AmnioBlast, as well as traditional allografts used in dental, spine, and orthopedic surgeries. The company aims to provide innovative solutions for enhancing bone fusion, wound repair, and tissue regeneration in various clinical applications, serving hospitals and surgeons globally.

What do analysts say about LBLTF stock?

As of March 17, 2026, there is no readily available analyst consensus on LBLTF stock due to its listing on the OTC market and limited coverage. Key valuation metrics such as price-to-earnings ratio (-0.01) and profit margin (-60.2%) indicate financial challenges. Growth considerations include the potential for revenue expansion through new product launches and strategic partnerships. Investors should conduct thorough due diligence and consider the risks associated with OTC-listed companies before making investment decisions.

What are the main risks for LBLTF?

The main risks for Lattice Biologics Ltd. include its negative profit margin, indicating ongoing financial challenges. The company's reliance on the OTC market for trading exposes it to liquidity risks and higher price volatility. Competition from larger, established medical device companies poses a threat to market share. Regulatory hurdles and potential product liability claims also represent significant risks. Investors should carefully consider these factors before investing in LBLTF.